🔗 Share this article

The first new treatments for gonorrhoea in a generation are being hailed as a "significant breakthrough" in the effort against increasingly resistant strains of the bacteria, according to health experts.

An International Health Concern

The sexually transmitted infection are on the rise worldwide, with estimates suggesting in excess of 82 million instances each year. Especially elevated rates are observed in the African continent and countries within the WHO's designated area, which encompasses Mongolia and China to New Zealand. Across England, cases have reached a historical peak, while infection numbers across Europe in 2023 were three times higher compared to those in 2014.

“The authorization of novel therapies for gonorrhoea is an critical and opportune advancement in the reality of increasing worldwide cases, escalating drug resistance and the very limited treatment choices at this time.”

Medical experts are deeply concerned about the increase in treatment-resistant strains. The WHO has classified it as a "priority pathogen". Recent surveillance found that the effectiveness of key first-line drugs like cefixime and ceftriaxone increased dramatically between 2022 and 2024.

A Pair of Novel Treatment Options Gain Authorization

Zoliflodacin, marketed under the name Nuzolvence, was authorized by the American regulatory agency in mid-December for treating gonorrhoea. This infection can lead to serious health problems, including infertility. Scientists anticipate that specific application of this new drug will help slow the development of resistance.

Gepotidacin, developed by the drugmaker GSK, also received approval in the same week. This treatment, which is additionally indicated for UTIs, was shown in trials to be effective against antibiotic-resistant forms of the gonorrhoea bacteria.

An Innovative Partnership

This new treatment stemmed from a innovative non-profit model for drug creation. The non-profit organisation GARDP worked alongside the drug firm its industry partner to bring it to fruition.

“This authorization signifies a significant shift in the treatment of multidrug-resistant gonorrhoea, which until now has been staying ahead of our drug pipeline.”

Research Study Outcomes and Global Access

Based on results released by a prominent scientific publication, the new drug cured the vast majority of cases of the STI. This establishes an equal footing with the current standard treatment, which uses a dual-drug approach. The research involved nearly 1,000 volunteers from various regions including the United States, Thailand, South Africa, and European nations.

Under the terms of its collaboration, the non-profit has the ability to license and sell the drug in a wide range of low-income and middle-income countries.

Medical professionals on the front lines have expressed hope. The availability of a one-pill regimen such as this is seen as a "game-changer" for public health efforts. This is considered vital to lessen the impact of the disease for individuals and to prevent the spread of untreatable gonorrhoea around the world.